The study enrolled 41 adolescents with obesity receiving liraglutide in Taiwan [1]. Other research on how long teens stay on GLP-1 drugs looks at treatment beyond the first prescription. This study measured changes at weeks 13 and 26.
How much did weight change?
Average weight fell 2.7 kg by week 13 and 4.4 kg by week 26 [1]. The corresponding standard deviations were 3.8 kg and 5.7 kg. These figures show variation. They do not tell us how many participants gained weight. Nineteen participants had a history of liver impairment.
The study had no untreated comparison group. Differences in when GLP-1 effects show up can matter when comparing milestones across studies. This study cannot separate the effect of liraglutide from growth, clinic support or other changes.
How the study dose compares with the US label
Mean daily dose in this study was 1.4 mg [1]. That describes what this group received in practice. The US Saxenda label covers eligible patients aged 12 or older with obesity and weight over 60 kg [2]. Its recommended pediatric maintenance dose is 3 mg daily, with 2.4 mg as an option if 3 mg is not tolerated. The study cannot tell families which dose to choose.
What the study found on side effects
Eight of 41 participants reported adverse events, all mild [1]. Stomach or intestinal symptoms were most frequent. Nobody stopped treatment because of intolerance. A study this small cannot reliably detect uncommon side effects.